http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 07:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jun+02/26587269.html si-local-file:///var/storage/secattach/20260602/26587269.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jun+02/26587269.html Tue, 02 Jun 2026 07:02:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jun+02/26587269.html si-local-file:///var/storage/secattach/20260602/26587269.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jun+02/26587269.html Tue, 02 Jun 2026 07:02:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jun+02/26587269.html si-local-file:///var/storage/secattach/20260602/26587269.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+Jun+02/26587269.html Tue, 02 Jun 2026 07:02:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+May+28/26567893.html si-local-file:///var/storage/secattach/20260528/26567893.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+May+28/26567893.html Thu, 28 May 2026 16:30:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+May+28/26567893.html si-local-file:///var/storage/secattach/20260528/26567893.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+May+28/26567893.html Thu, 28 May 2026 16:30:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+May+28/26567893.html si-local-file:///var/storage/secattach/20260528/26567893.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+May+28/26567893.html Thu, 28 May 2026 16:30:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+May+18/26510021.html si-local-file:///var/storage/secattach/20260518/26510021.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+May+18/26510021.html Mon, 18 May 2026 07:02:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+May+18/26510021.html si-local-file:///var/storage/secattach/20260518/26510021.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+May+18/26510021.html Mon, 18 May 2026 07:02:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+May+18/26510021.html si-local-file:///var/storage/secattach/20260518/26510021.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Can-Fite+BioPharma+Ltd.+++For%3A+May+18/26510021.html Mon, 18 May 2026 07:02:00 -0400 CANF CANF O.05892622 http://www.streetinsider.com/Corporate+News/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced the publication of a peer-reviewed scientific article detailing positive findings from a study of its drug Piclidenoson for treating canine osteoarthritis. The article appeared in the journal Frontiers in Veterinary Science.</p><p>The study showed that oral treatment with Piclidenoson resulted in statistically significant improvement in mobility and pain assessments in dogs with osteoarthritis. Key findings included significant improvement in Liverpool Osteoarthritis in Dogs scores for dogs treated with Piclidenoson at 500 µg/kg twice daily, significant reduction in pain scores measured by Visual Analog Scale, and significant reduction in veterinarian-assessed lameness and pain.</p><p>The study reported http://www.streetinsider.com/Corporate+News/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html Mon, 18 May 2026 07:01:49 -0400 CANF CFBI http://www.streetinsider.com/Corporate+News/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced the publication of a peer-reviewed scientific article detailing positive findings from a study of its drug Piclidenoson for treating canine osteoarthritis. The article appeared in the journal Frontiers in Veterinary Science.</p><p>The study showed that oral treatment with Piclidenoson resulted in statistically significant improvement in mobility and pain assessments in dogs with osteoarthritis. Key findings included significant improvement in Liverpool Osteoarthritis in Dogs scores for dogs treated with Piclidenoson at 500 µg/kg twice daily, significant reduction in pain scores measured by Visual Analog Scale, and significant reduction in veterinarian-assessed lameness and pain.</p><p>The study reported http://www.streetinsider.com/Corporate+News/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html Mon, 18 May 2026 07:01:49 -0400 CANF CFBI http://www.streetinsider.com/FDA/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced the publication of a peer-reviewed scientific article detailing positive findings from a study of its drug Piclidenoson for treating canine osteoarthritis. The article appeared in the journal Frontiers in Veterinary Science.</p><p>The study showed that oral treatment with Piclidenoson resulted in statistically significant improvement in mobility and pain assessments in dogs with osteoarthritis. Key findings included significant improvement in Liverpool Osteoarthritis in Dogs scores for dogs treated with Piclidenoson at 500 µg/kg twice daily, significant reduction in pain scores measured by Visual Analog Scale, and significant reduction in veterinarian-assessed lameness and pain.</p><p>The study reported http://www.streetinsider.com/FDA/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html Mon, 18 May 2026 07:01:49 -0400 CANF CFBI http://www.streetinsider.com/FDA/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html <p>Can-Fite BioPharma Ltd. (NYSE American: CANF) announced the publication of a peer-reviewed scientific article detailing positive findings from a study of its drug Piclidenoson for treating canine osteoarthritis. The article appeared in the journal Frontiers in Veterinary Science.</p><p>The study showed that oral treatment with Piclidenoson resulted in statistically significant improvement in mobility and pain assessments in dogs with osteoarthritis. Key findings included significant improvement in Liverpool Osteoarthritis in Dogs scores for dogs treated with Piclidenoson at 500 µg/kg twice daily, significant reduction in pain scores measured by Visual Analog Scale, and significant reduction in veterinarian-assessed lameness and pain.</p><p>The study reported http://www.streetinsider.com/FDA/Can-Fite+publishes+study+results+on+canine+osteoarthritis+drug/26510017.html Mon, 18 May 2026 07:01:49 -0400 CANF CFBI http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Press+Releases/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344 http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html <p align="justify">Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) --  <a target="_blank" href="https://www.globenewswire.com/Tracker?data=5ObYD4l-0U1JquN8RCtZyeF4UERsfuRimhFpjUY795wyHeJqV6J-SZx-1N1QMq2nhqlOTzKCzsRJ8C0AviONblYc42Cdf_TcaqlrAgcpw1A=" rel="nofollow" target="_blank">Can-Fite BioPharma</a> Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced publication of a peer-reviewed scientific article regarding previously reported positive findings from a study evaluating Piclidenoson for the treatment of canine osteoarthritis. The article abstract, titled <i>“</i><a target="_blank" href="https://www.globenewswire.com/Tracker?data=gjcJUHEZdtrpvhfQhbYQKfZdDY_nfWRWUzZPpafhhgggdIMvUuWcJdmj8yCF01tDOATBdcFnqpe8CEYR--pkVTQjAlcN_KalO_bioy-I5w7GfUS-3772ToJugU6MzYsFGjUN-SJ06fsXKZeiVxfTcvw_eghodTLNZNqvEgmjkQYMybEU7NrG9SX4MzQp85GI4fhtF_M5R-xsXDcD0UFfphxns9nQINK61xo1RKoKP5DvMduHwgP3rdYyMXImgaybtgkqGFy-A6XgRg3K-cAbG0GLAmvxS_kYOi0nY-4MZqq_DWgS-NGYBGHQyQBGg2Ax" rel="nofollow" target="_blank"><i>Piclidenoson, an A3 Adenosine Receptor Agonist, Improves Clinical Signs in Dogs with Osteoarthritis</i></a><i>”</i> was published in the peer-reviewed journal <i>Frontiers in Veterinary Science</i> and is available online.</p> http://www.streetinsider.com/Globe+Newswire/Scientific+Publication+of+Can-Fite+and+Vetbiolix+Validates+Piclidenoson%E2%80%99s+Potential+in+the+Multi-Billion+Dollar+Canine+Osteoarthritis+Market/26509967.html Mon, 18 May 2026 07:00:00 -0400 A.06822034 CANF CANF CFBI O.05892622 O.20026344